Oppositely, cultivation of breast cancer cells with CXCR4 antagonist, AMD3100, sensitized mesenchymal stem cells to cytotoxic drugs and reduced tumor metastatic burden [21]. This evidence concerns the gene CXCR4 and breast carcinoma.